EyePoint Pharmaceuticals/$EYPT
1D1W1MYTD1Y5YMAX
Capital at risk
About EyePoint Pharmaceuticals
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
- Ticker
- $EYPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Watertown, United States
- Website
- eyepoint.bio
EYPT Metrics
BasicAdvanced
$366M
-
-$3.76
1.74
-
Price and volume
Market cap
$366M
Beta
1.74
52-week high
$19.11
52-week low
$3.95
Average daily volume
5.5M
Financial strength
Current ratio
4.502
Quick ratio
4.305
Long term debt to equity
0.119
Total debt to equity
0.134
Interest coverage (TTM)
-9,605.33%
Profitability
EBITDA (TTM)
-314.376
Gross margin (TTM)
-9,235.01%
Net profit margin (TTM)
-10,998.67%
Operating margin (TTM)
-11,369.30%
Effective tax rate (TTM)
-0.04%
Management effectiveness
Return on assets (TTM)
-74.85%
Return on equity (TTM)
-148.70%
Valuation
Price to revenue (TTM)
124.185
Price to book
2.17
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-1.276
Free cash flow yield (TTM)
-78.35%
Free cash flow per share (TTM)
-3.33
Growth
Revenue change (TTM)
-94.63%
Earnings per share change (TTM)
38.85%
3-year revenue growth (CAGR)
-57.89%
3-year earnings per share growth (CAGR)
9.97%
What the Analysts think about EYPT
Analyst ratings (Buy, Hold, Sell) for EyePoint Pharmaceuticals stock.
Analyst projections of the future price of EyePoint Pharmaceuticals stock.
Bulls say / Bears say
Despite the LUGANO primary-endpoint miss, DURAVYU produced a 42% reduction in treatment burden versus aflibercept, with 54% of patients remaining supplement-free through Week 56 and 79% receiving zero or one supplemental injection. These results could support meaningful differentiation if confirmed in LUCIA and accepted by regulators. (EyePoint)
EyePoint completed enrollment in both pivotal Phase 3 DME trials in only five months, enrolling more than 480 patients. Rapid enrollment and a second large retinal-disease opportunity preserve upside beyond wet AMD, although topline DME data are not expected until Q4 2027. (EyePoint)
The company reported $180 million in cash, cash equivalents, and marketable securities as of June 30, 2026, and expects this balance to fund operations into Q4 2027 beyond key wet-AMD milestones. That runway reduces near-term financing pressure while investors await LUCIA and further clinical data. (SEC filing)
DURAVYU failed to meet the full-dataset primary endpoint in the pivotal LUGANO wet-AMD trial, despite passing an ad hoc analysis that excluded an asymmetric group of patients. This materially raises regulatory and investor risk ahead of the second pivotal readout. (Reuters)
EyePoint remains deeply loss-making while spending escalates: Q2 operating expenses rose to $97.9 million, net loss reached $94.5 million, and cash and marketable securities fell to $180 million from $223 million in the prior quarter. Continued development and manufacturing investment could increase dilution or financing risk if milestones are delayed. (SEC filing)
The investment case remains heavily dependent on DURAVYU, which is still unapproved; after the LUGANO miss, the company needs supportive LUCIA results expected in Q4 2026, while DME efficacy data are not expected until Q4 2027. Any further setback could materially weaken the company’s path to commercialization. (EyePoint)
Data summarised monthly by Lightyear AI. Last updated on 13 Sept 2026.
EYPT Financial Performance
Revenues and expenses
EYPT Earnings Performance
Company profitability
Upcoming events
No upcoming events
EYPT News
AllArticlesVideos
EYPT SHAREHOLDER ALERT: EyePoint Pharmaceuticals Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Business Wire2 weeks ago
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
Business Wire3 weeks ago
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Business Wire3 weeks ago
Funds containing EYPT
AllEURUSDGBP
Fund name | Fund size | $EYPT weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.